| Literature DB >> 33816570 |
Jinke Huang1, Xiaohui Qin2, Min Shen3, Yanjuan Xu1, Yong Huang4.
Abstract
Background: Tai chi (TC) is a popular form of exercise among adults with chronic heart failure (CHF), yet services are greatly underutilized. The aim of the current study was to identify and summarize the existing evidence and to systematically determine the clinical effectiveness of Tai Chi in the management of CHF using a systematic overview.Entities:
Keywords: AMSTAR-2; GRADE; PRISMA; ROBIS; Tai Chi; heart failure; overview
Year: 2021 PMID: 33816570 PMCID: PMC8012482 DOI: 10.3389/fcvm.2021.589267
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1Flow diagram of the literature selection process.
Review characteristics.
| Taylor-Piliae and Finley ( | 6 (229) | TC + CM | CM | Downs and Black Quality Index checklist | Among adults with CHF, TC was effective in improving exercise capacity and QoL, with less depression and B-type natriuretic peptide levels observed, when compared with controls. TC is a safe form of exercise and can be easily integrated into existing cardiac rehabilitation programs. Further research is needed with rigorous study designs and larger samples before widespread recommendations can be made. |
| Li et al. ( | 7 (4,46) | TC + CM | CM | Cochrane | TC can significantly improve the heart function and quality of life for the patients with heart failure, and this treatment could be applied to the rehabilitation process of patients with stable heart failure. |
| Wei et al. ( | 10 (689) | TC + CM | CM | Cochrane | The current evidence shows that TC is feasible for patients with heart failure as it has positive effects on life quality, physiological functions. Due to the limited quality and quantity of included studies, the above conclusion should be validated by more high quality studies. |
| Ren et al. ( | 11 (656) | TC + CM | CM | Cochrane | TC could improve 6MWD, quality of life and LVEF in patients with HF and may reduce BNP and HR. However, there is a lack of evidence to support TC altering other important long-term clinical outcomes so far. Further larger and more sustainable RCTs are urgently needed to investigate the effects of TC. |
| Gu et al. ( | 10 (904) | TC + CM | CM | Cochrane | Despite heterogeneity and risk of bias, this meta-analysis further confirms that TC may be an effective cardiac rehabilitation method for patients with chronic heart failure. Larger, well-designed RCTs are needed to exclude the risk of bias. |
| Pan et al. ( | 4 (242) | TC + CM | CM | Jadad | TC may improve quality of life in patients with CHF and could be considered for inclusion in cardiac rehabilitation programs. However, there is currently a lack of evidence to support TC altering other important clinical outcomes. Further larger RCTs are urgently needed to investigate the effects of TC. |
Result of the AMSTAR-2 assessments.
| Taylor-Piliae and Finley ( | Y | PY | Y | Y | Y | Y | N | Y | Y | N | Y | Y | Y | Y | Y | N | CL |
| Li et al. ( | Y | PY | Y | PY | Y | Y | N | Y | Y | N | Y | Y | Y | Y | Y | N | CL |
| Wei et al. ( | Y | PY | Y | Y | Y | Y | N | Y | Y | N | Y | Y | Y | Y | N | N | CL |
| Ren et al. ( | Y | PY | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | CL |
| Gu et al. ( | Y | PY | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | CL |
| Pan et al. ( | Y | PY | Y | Y | Y | Y | N | Y | Y | N | Y | Y | Y | Y | Y | N | CL |
Y, Yes; PY, partial Yes; N, No; CL, Critically low; L, Low; H, High.
Result of the PRISMA assessments.
| Title | Q1. Title | Y | Y | Y | Y | Y | Y | 100% |
| Abstract | Q2. Structured summary | Y | Y | Y | Y | Y | Y | 100% |
| Introduction | Q3. Rationale | Y | Y | Y | Y | Y | Y | 100% |
| Q4. Objectives | Y | Y | Y | Y | Y | Y | 100% | |
| Methods | Q5. Protocol and registration | N | N | N | N | N | N | 0% |
| Q6. Eligibility criteria | Y | Y | Y | Y | Y | Y | 100% | |
| Q7. Information sources | Y | Y | Y | Y | Y | Y | 100% | |
| Q8. Search | Y | PY | Y | Y | Y | Y | 83.3% | |
| Q9. Study selection | Y | Y | Y | Y | Y | Y | 100% | |
| Q10. Data collection process | Y | Y | Y | Y | Y | Y | 100% | |
| Q11. Data items | Y | Y | Y | Y | Y | Y | 100% | |
| Q12. Risk of bias in individual studies | Y | Y | Y | Y | Y | Y | 100% | |
| Q13. Summary measures | Y | Y | Y | Y | Y | Y | 100% | |
| Q14. Synthesis of results | Y | Y | Y | Y | Y | Y | 100% | |
| Q15. Risk of bias across studies | N | Y | N | Y | Y | Y | 33.3% | |
| Q16. Additional analyses | N | Y | Y | Y | Y | Y | 83.3% | |
| Results | Q17. Study selection | Y | Y | Y | Y | Y | Y | 100% |
| Q18. Study characteristics | Y | Y | Y | Y | Y | Y | 100% | |
| Q19. Risk of bias within studies | Y | Y | Y | Y | Y | Y | 100% | |
| Q20. Results of individual studies | Y | Y | Y | Y | Y | Y | 100% | |
| Q21. Synthesis of results | Y | Y | Y | Y | Y | Y | 100% | |
| Q22. Risk of bias across studies | N | Y | N | Y | Y | Y | 66.7% | |
| Q23. Additional analysis | N | Y | Y | Y | Y | Y | 66.7% | |
| Discussion | Q24. Summary of evidence | Y | Y | Y | Y | Y | Y | 100% |
| Q25. Limitations | Y | Y | Y | Y | Y | Y | 100% | |
| Q26. Conclusions | Y | Y | Y | Y | Y | Y | 100% | |
| Funding | Q27. Funding | N | N | N | Y | Y | N | 33.3% |
Result of the ROBIS assessments.
| Taylor-Piliae and Finley ( | ||||||
| Li et al. ( | ||||||
| Wei et al. ( | ||||||
| Ren et al. ( | ||||||
| Gu et al. ( | ||||||
| Pan et al. ( | ||||||
.
Results of evidence quality.
| Taylor-Piliae and Finley ( | 6-MWT | 5 | Rct | No | No | No | Serious | No | 135 | 134 | SMD 0.353 (0.041, 0.664) | 0.026 | ⊕⊕⊕⊕○ |
| QoL | 5 | Rct | No | No | No | Serious | No | 135 | 134 | SMD −0.671 (−0.864, −0.370) | 0.000 | ⊕⊕⊕⊕○ | |
| BNP | 4 | Rct | No | No | No | Serious | No | 103 | 103 | SMD −0.333 (−0.604, −0.062) | 0.016 | ⊕⊕⊕⊕○ | |
| Li et al. ( | LVEF | 3 | Rct | No | Serious | No | Serious | No | 128 | 108 | MD 8.38 (6.98, 9.78) | <0.0001 | ⊕⊕⊕○○ |
| 6-MWT | 5 | Rct | No | No | No | No | No | 161 | 151 | SMD 0.85 (0.61, 1.08) | <0.0001 | ⊕⊕⊕⊕⊕ | |
| QoL | 4 | Rct | No | Serious | No | Serious | No | 131 | 122 | SMD −1.10 (−1.91, −0.29) | 0.008 | ⊕⊕⊕○○ | |
| NT-proBNP | 2 | Rct | No | No | No | Serious | Serious | 45 | 45 | SMD −12.14 (−23.78, −0.50) | 0.04 | ⊕⊕⊕○○ | |
| Wei et al. ( | QoL | 7 | Rct | Serious | Serious | No | No | No | 279 | 270 | MD −9.37 (−13.09, −5.65) | <0.0001 | ⊕⊕⊕○○ |
| 6-MWT | 7 | Rct | Serious | Serious | No | No | No | 277 | 267 | MD 40.37 (9.48, 71.27) | 0.01 | ⊕⊕⊕○○ | |
| LVEF | 5 | Rct | Serious | Serious | No | No | No | 212 | 202 | MD 7.89 (3.01, 12.77) | 0.002 | ⊕⊕⊕○○ | |
| BNP | 5 | Rct | Serious | No | No | No | No | 162 | 162 | MD −10.75 (−13.20, −8.30) | <0.0001 | ⊕⊕⊕⊕○ | |
| Peak VO2 | 3 | Rct | Serious | No | No | Serious | Serious | 73 | 73 | MD 0.29 (−1.23, 1.81) | 0.71 | ⊕⊕○○○ | |
| SBP | 4 | Rct | Serious | No | No | Serious | Serious | 80 | 81 | MD −2.81 (−8.52, 2.90) | 0.33 | ⊕⊕○○○ | |
| DBP | 3 | Rct | Serious | No | No | Serious | Serious | 70 | 71 | MD 0.37 (−3.73, 4.48) | 0.86 | ⊕⊕○○○ | |
| Ren et al. ( | 6-MWT | 7 | Rct | Serious | Serious | No | No | No | 241 | 233 | WMD 65.29 (−32.55, 98.04) | <0.001 | ⊕⊕⊕○○ |
| QoL | 7 | Rct | Serious | Serious | No | No | No | 236 | 230 | WMD −11.52 (−16.5, −6.98) | <0.001 | ⊕⊕⊕○○ | |
| BNP | 5 | Rct | Serious | Serious | No | No | No | 133 | 133 | SMD −1.08 (−1.91, −0.26) | <0.001 | ⊕⊕⊕○○ | |
| LVEF | 5 | Rct | Serious | Serious | No | No | No | 200 | 180 | WMD 9.94% (6.95, 12.93) | <0.001 | ⊕⊕⊕○○ | |
| HR | 2 | Rct | Serious | No | No | Serious | Serious | 38 | 38 | WMD −2.52 (−3.49, −1.55) | <0.001 | ⊕⊕○○○ | |
| Gu et al. ( | 6-MWT | 10 | Rct | Serious | Serious | No | No | No | 344 | 379 | WMD 51.01 (30.49, 71.53) | <0.001 | ⊕⊕⊕○○ |
| QoL | 8 | Rct | Serious | Serious | No | No | No | 280 | 318 | WMD −10.37 (−14.43, −6.32) | <0.001 | ⊕⊕⊕○○ | |
| LVEF | 7 | Rct | Serious | Serious | No | No | No | 283 | 306 | WMD 7.72% (3.58, 11.89) | 0.003 | ⊕⊕⊕○○ | |
| BNP | 6 | Rct | Serious | Serious | No | No | No | 178 | 221 | SMD −1.01(−1.82, −0.19) | 0.02 | ⊕⊕⊕○○ | |
| Pan et al. ( | 6-MWT | 3 | Rct | Serious | No | No | Serious | No | 95 | 95 | MD 46.73 (−1.62, 95.09) | 0.06 | ⊕⊕⊕○○ |
| QoL | 3 | Rct | No | Serious | No | Serious | No | 90 | 92 | WMD −14.54 (−23.45, −5.63) | 0.001 | ⊕○○○○ | |
| BNP | 2 | Rct | No | Serious | No | Serious | Serious | 45 | 45 | MD −61.16 (−179.27, −56.95) | 0.31 | ⊕⊕○○○ | |
| SBP | 2 | Rct | Serious | Serious | No | Serious | Serious | 55 | 57 | MD −1.06 (−13.76, 11.63) | 0.87 | ⊕○○○○ | |
| DBP | 2 | Rct | Serious | Serious | No | Serious | Serious | 55 | 57 | MD −0.08 (−3.88, 3.73) | 0.97 | ⊕○○○○ | |
| Peak VO2 | 2 | Rct | No | No | No | Serious | Serious | 65 | 65 | MD 0.19 (−0.74, 1.13) | 0.68 | ⊕○○○○ | |
CI, Confidence interval; WMD, weighted mean difference; MD, mean difference; SMD, standardized mean difference.
The experimental design had a large bias in random, distributive findings or was blind.
The confidence interval overlap less, the heterogeneity test P was very small, and the I.
The Confidence interval was not narrow enough, or the simple size is too small.
Funnel graph asymmetry, or fewer studies were included and there may have been greater publication bias.